Yeoungjee Cho1, David W Johnson1, David A Vesey1, Carmel M Hawley1, Elaine M Pascoe2, Margaret Clarke2, Nicholas Topley2. 1. Department of Renal Medicine, Princess Alexandra Hospital, Brisbane, Australia; School of Medicine, University of Queensland, Brisbane, Australia; Translational Research Institute, Brisbane, Australia; Fresenius Medical Care, Sydney, Australia; Institute of Translation, Innovation, Methodology and Engagement, Cardiff University School of Medicine, Cardiff, UK Department of Renal Medicine, Princess Alexandra Hospital, Brisbane, Australia; School of Medicine, University of Queensland, Brisbane, Australia; Translational Research Institute, Brisbane, Australia; Fresenius Medical Care, Sydney, Australia; Institute of Translation, Innovation, Methodology and Engagement, Cardiff University School of Medicine, Cardiff, UK Department of Renal Medicine, Princess Alexandra Hospital, Brisbane, Australia; School of Medicine, University of Queensland, Brisbane, Australia; Translational Research Institute, Brisbane, Australia; Fresenius Medical Care, Sydney, Australia; Institute of Translation, Innovation, Methodology and Engagement, Cardiff University School of Medicine, Cardiff, UK. 2. Department of Renal Medicine, Princess Alexandra Hospital, Brisbane, Australia; School of Medicine, University of Queensland, Brisbane, Australia; Translational Research Institute, Brisbane, Australia; Fresenius Medical Care, Sydney, Australia; Institute of Translation, Innovation, Methodology and Engagement, Cardiff University School of Medicine, Cardiff, UK.
Abstract
BACKGROUND: The utility of local and systemic interleukin 6 (IL-6) as a prognostic marker in incident peritoneal dialysis (PD) patients remains to be fully defined. The present study aimed to explore the capacity of systemic IL-6 concentrations to predict cardiovascular events (CVEs) and mortality in PD patients, and to evaluate the influence of neutral-pH PD solutions low in glucose degradation products (GDPs) on systemic IL-6. METHODS: The study included 175 incident participants from the balANZ trial with at least one stored serum sample. A composite CVE score was used as the primary clinical outcome measure. Multilevel linear regression and Poisson regression models were fitted to describe, respectively, the trend of serum IL-6 over time and its ability to predict composite CVE. RESULTS: A significant increase in serum IL-6 from baseline to 24 months was observed in the study population (mean difference: 1.68 pg/mL; p = 0.006). The type of PD solution received by patients exerted no significant effect on serum IL-6 (p = 0.12). Composite CVE was significantly and independently associated with baseline serum IL-6 (incidence rate ratio per picogram per milliliter: 1.06; 95% confidence interval: 1.02 to 1.10; p = 0.003). CONCLUSIONS: Baseline serum IL-6 was a significant independent predictor of composite CVE. Serum IL-6 concentrations increased with increasing PD duration and were not significantly modified with the use of biocompatible fluid over the study period. The present study is the first to link systemic IL-6 concentrations with CVE outcomes in incident PD patients.
BACKGROUND: The utility of local and systemic interleukin 6 (IL-6) as a prognostic marker in incident peritoneal dialysis (PD) patients remains to be fully defined. The present study aimed to explore the capacity of systemic IL-6 concentrations to predict cardiovascular events (CVEs) and mortality in PDpatients, and to evaluate the influence of neutral-pH PD solutions low in glucose degradation products (GDPs) on systemic IL-6. METHODS: The study included 175 incident participants from the balANZ trial with at least one stored serum sample. A composite CVE score was used as the primary clinical outcome measure. Multilevel linear regression and Poisson regression models were fitted to describe, respectively, the trend of serum IL-6 over time and its ability to predict composite CVE. RESULTS: A significant increase in serum IL-6 from baseline to 24 months was observed in the study population (mean difference: 1.68 pg/mL; p = 0.006). The type of PD solution received by patients exerted no significant effect on serum IL-6 (p = 0.12). Composite CVE was significantly and independently associated with baseline serum IL-6 (incidence rate ratio per picogram per milliliter: 1.06; 95% confidence interval: 1.02 to 1.10; p = 0.003). CONCLUSIONS: Baseline serum IL-6 was a significant independent predictor of composite CVE. Serum IL-6 concentrations increased with increasing PD duration and were not significantly modified with the use of biocompatible fluid over the study period. The present study is the first to link systemic IL-6 concentrations with CVE outcomes in incident PDpatients.
Authors: Kar Neng Lai; Man Fai Lam; Joseph C K Leung; Loretta Y Chan; Christopher W K Lam; Iris H S Chan; Hoi Wong Chan; Chun Sang Li; Sunny S H Wong; Yiu Wing Ho; Au Cheuk; Matthew K L Tong; Sydney C W Tang Journal: Perit Dial Int Date: 2011-11-03 Impact factor: 1.756
Authors: Yongmei Liu; Yvette Berthier-Schaad; Margaret D Fallin; Nancy E Fink; Russell P Tracy; Michael J Klag; Michael W Smith; Josef Coresh Journal: J Am Soc Nephrol Date: 2006-02-08 Impact factor: 10.121
Authors: Lars Weiss; Bernd Stegmayr; Gudrun Malmsten; Mattias Tejde; Henrik Hadimeri; Carl E Siegert; Jarl Ahlmén; Rutger Larsson; Bo Ingman; Ole Simonsen; Henk W van Hamersvelt; Ann C Johansson; Britta Hylander; Michael Mayr; Per-Henrik Nilsson; Per O Andersson; Tatiana De los Ríos Journal: Perit Dial Int Date: 2009 Nov-Dec Impact factor: 1.756
Authors: David W Johnson; Hannah Dent; Carmel M Hawley; Stephen P McDonald; Johan B Rosman; Fiona G Brown; Kym Bannister; Kathryn J Wiggins Journal: Clin J Am Soc Nephrol Date: 2009-09-03 Impact factor: 8.237
Authors: Yeoungjee Cho; Janine Büchel; Sonja Steppan; Jutta Passlick-Deetjen; Carmel M Hawley; Goce Dimeski; Margaret Clarke; David W Johnson Journal: Perit Dial Int Date: 2015-10-01 Impact factor: 1.756
Authors: J Haybrard; N Simon; C Danel; C Pinçon; C Barthélémy; F J Tessier; B Décaudin; E Boulanger; P Odou Journal: Sci Rep Date: 2017-09-20 Impact factor: 4.379
Authors: Joseph C Gigliotti; Liping Huang; Amandeep Bajwa; Hong Ye; Eric H Mace; John A Hossack; Kambiz Kalantari; Tsuyoshi Inoue; Diane L Rosin; Mark D Okusa Journal: J Am Soc Nephrol Date: 2015-02-02 Impact factor: 10.121
Authors: Aminu K Bello; Ikechi G Okpechi; Mohamed A Osman; Yeoungjee Cho; Brett Cullis; Htay Htay; Vivekanand Jha; Muhammad A Makusidi; Mignon McCulloch; Nikhil Shah; Marina Wainstein; David W Johnson Journal: Nat Rev Nephrol Date: 2022-09-16 Impact factor: 42.439